Literature DB >> 8005243

Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up.

C Agustí1, A Xaubet, A G Agustí, J Roca, J Ramirez, R Rodriguez-Roisin.   

Abstract

The purpose of this study was to analyse the information provided by different techniques used in the assessment of patients with idiopathic pulmonary fibrosis (IPF) and their role in the prediction of lung function decline with the decline. Twenty seven subjects with IPF (55 +/- 14 (mean +/- SD) yrs) were studied at the initial staging. Nineteen of them (70%) were included in a follow-up over 3 yrs (32 +/- 6 months), whilst the remaining 8 patients were lost to follow-up. During the period of the study, 6 of the 19 patients died. A significant correlation between diffusing capacity of the lungs for carbon monoxide (DLCO) (and carbon monoxide transfer coefficient (KCO) = DLCO/alveolar volume (VA)) and the increase in alveolar-arterial oxygen tension difference (A-aPO2) during exercise (delta A-aPO2) was observed at diagnosis (r = -0.58). Despite the treatment with prednisone (1 mg.kg-1 daily during 4 weeks, tapered to an individualized maintenance daily dose of 15-30 mg), the 13 patients controlled throughout the whole period of the study showed a marked impairment in lung volumes; forced vital capacity (FVC) -0.46 +/- 0.09 l, from 69 +/- 16 to 52 +/- 11% of predicted, and total lung capacity (TLC) -0.39 +/- 0.11 l, from 75 +/- 16 to 62 +/- 14%, and in DLCO -0.6 +/- 0.2 mmol.min-1.kPa-1, from 56 +/- 15 to 47 +/- 18%, predicted. By contrast, both mean arterial oxygen tension (PaO2) and A-aPO2 at rest remained unchanged throughout the 3 yrs follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005243     DOI: 10.1183/09031936.94.07040643

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

Review 1.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

2.  Radiographic (ILO) readings predict arterial oxygen desaturation during exercise in subjects with asbestosis.

Authors:  Y C G Lee; B Singh; S C Pang; N H de Klerk; D R Hillman; A W Musk
Journal:  Occup Environ Med       Date:  2003-03       Impact factor: 4.402

Review 3.  Pulmonary function testing in idiopathic interstitial pneumonias.

Authors:  Fernando J Martinez; Kevin Flaherty
Journal:  Proc Am Thorac Soc       Date:  2006-06

4.  Mortality rates from cryptogenic fibrosing alveolitis in seven countries.

Authors:  R Hubbard; I Johnston; D B Coultas; J Britton
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

5.  Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression.

Authors:  M Molina-Molina; A Xaubet; X Li; A Abdul-Hafez; K Friderici; K Jernigan; W Fu; Q Ding; J Pereda; A Serrano-Mollar; A Casanova; E Rodríguez-Becerra; F Morell; J Ancochea; C Picado; B D Uhal
Journal:  Eur Respir J       Date:  2008-05-28       Impact factor: 16.671

6.  Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis.

Authors:  C Agusti; A Xaubet; P Luburich; M C Ayuso; J Roca; R Rodriguez-Roisin
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

7.  Exercise Tolerance in Patients With Idiopathic Pulmonary Fibrosis, Effect of Supplemental Oxy-Gen.

Authors:  J Chlumský; L Stehlík; M Šterclová; J Smetanová; O Zindr
Journal:  Physiol Res       Date:  2022-04-11       Impact factor: 2.139

8.  Change in pulmonary diffusion capacity in a general population sample over 9 years.

Authors:  Michael L Storebø; Tomas M L Eagan; Geir E Eide; Amund Gulsvik; Einar Thorsen; Per S Bakke
Journal:  Eur Clin Respir J       Date:  2016-09-02

9.  Do we need exercise tests to detect gas exchange impairment in fibrotic idiopathic interstitial pneumonias?

Authors:  Benoit Wallaert; Lidwine Wemeau-Stervinou; Julia Salleron; Isabelle Tillie-Leblond; Thierry Perez
Journal:  Pulm Med       Date:  2012-07-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.